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PCN151
PatieNt RePoRted outComes iN CastRatioN-ResistaNt PRostate 
CaNCeR
Aggarwal S., Segal J.
Novel Health Strategies, Bethesda, MD, USA
Objectives: Patient reported outcomes (PRO) are becoming useful tools for col-
lecting and generating evidence for new medical products to show improvements 
in health-related quality of life (HRQoL). Castration-Resistant Prostate Cancer 
(CRPC) is a chronic disease with high importance for patient HRQoL. The objective 
of this study was to review, analyze, and understand trends in the PRO instruments 
used in patients with CRPC. MethOds: A systematic literature search for CRPC 
randomized controlled trials (RCTs) with PROs endpoints was undertaken for the 
databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was col-
lected for the study size, interventions, year, PRO instrument, and results for PROs. 
Analysis was conducted to identify trends in commonly used PRO instruments 
and categorize results as positive, neutral or negative. Results: Ten RCTs with 
a total of 5,797 patients were identified. In these studies there were thirteen dif-
ferent PROs instruments were identified that were FACT-P, FACT-G, BPI-SF, EQC30, 
EQPR25, FLIC, SDS, SUF, PDA, IPDA, PROSQOLI, SF-36, and QOLM-P14. The most 
commonly used instrument were FACT-P (used in 4,297 patients) and EQC-30 (used 
in 1,091 patients). Six studies reported positive results with improvement in qual-
ity of life symptoms (QoL) versus comparator treatments. Fours studies reported 
results with deterioration in (QOL). Three studies reported improvement in pain 
scores. cOnclusiOns: Patients with CRPC have relatively longer survival and 
hence QoL is an important consideration for these patients. PRO instruments such 
as FACT-P and EQC-30 have been commonly used to generate evidence to show 
which therapies improve patient QoL.
PCN152
imPaCt of ColoReCtal CaNCeR oN aCtivities of daily liviNg aNd 
dePRessioN Risk amoNg oldeR ameRiCaNs
Quach C., Sanoff H.K., Williams G.R., Lyons J.C., Reeve B.B.
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Objectives: 1) Estimate change in activities of daily living (ADL) and risk for major 
depressive disorder (MDD) among older Americans > 64 years following diagnosis 
and treatment of colorectal cancer (CRC); 2) Compare change in ADL function and 
MDD risk among CRC patients to matched controls without cancer. MethOds: 
This population-based study used the Surveillance, Epidemiology, and End Results-
Medicare Health Outcomes Survey (SEER-MHOS) dataset (1998-2007). Medicare 
managed care beneficiaries diagnosed with CRC between completion of baseline 
and follow-up MHOS (n= 349) were matched to non-cancer controls (n= 1,745) using 
propensity scores. Analysis of covariance models estimated change in ability to 
perform six ADLs: bathing, dressing, eating, getting in or out of chairs, walking, 
using the toilet. Logistic regression was used to estimate MDD risk. Covariates 
included socio-demographic, clinical and survey characteristics. Results: Mean 
time from diagnosis to MHOS follow-up was 12.3 months (SD 9.8) for CRC patients 
(n= 103 Stage I, 122 Stage II, 95 Stage III, 29 Stage IV). Though patients and controls 
reported similar ADL impairment at baseline (.97 vs. .92; p= 0.06), CRC patients 
had greater impairment at follow-up (mean 2.21 vs. .92; p< 0.01). Mean increase 
in ADL impairment was 1.02 for Stage I, 1.25 for Stage II, 1.53 for Stage III, and 1.67 
for Stage IV patients (each p< 0.01). Compared to controls, CRC patients suffered 
greater impairment with respect to bathing (p= 0.01), getting in/out of chairs (p= 0.01) 
and walking (p< 0.01). CRC patients and controls had similar MDD risk at baseline 
(odds ratio [OR] 1.22 [95% confidence interval .94–1.58]) and at follow-up (OR 3.18 
[0.65–15.69]). cOnclusiOns: CRC has adverse effects on ADL functioning among 
older Americans—even in the early, curable stages. This study informs clinicians 
and caregivers of the need to identify opportunities to provide supportive care for 
patients’ basic needs of self-care.
PCN154
the Real imPaCt of Quality of life (Qol) eNdPoiNts oN maRket aCCess 
deCisioNs aCRoss maRkets – a Case study of oNCology PRoduCts
Gardiner R.B.1, Sealey S.1, Edathodu A.1, Mukku S.R.2
1Access Partnership, London, UK, 2The Access Partnership, London, UK
Objectives: Recent approvals of targeted oncology therapies have resulted in 
increased patient survival, and potential comorbidities. Subsequently, a greater 
emphasis has been placed on QoL, and PRO endpoints. However, the impact of QoL 
instruments on market access of new oncology products remains unclear. This 
research aims at understanding the true relevance of QoL endpoints in payer deci-
sion making MethOds: The research was conducted through in-depth secondary 
research and interviews with payers in 6 countries including the US, Germany, 
France, Spain, Italy, and Sweden. Results: In the markets studied, QoL data is a 
requirement to be submitted for reimbursement; however, it is not a key determi-
nant of reimbursement or pricing decisions at a national level. Some countries like 
Italy and Spain view QoL data as being important at a regional and local level for 
inclusion in formularies and guidelines. Furthermore, payers suggest that QoL is 
considered only in a qualitative sense based on the safety profile of a drug, and do 
not consider the instruments used to measure it. For example, in France, although 
the expectation is that a disease-specific QoL instrument is submitted for review 
by the Transparency Commission, this data will not contribute towards an ASMR 
determination. Meanwhile, in Sweden, the TLV requires the use of only generic 
instruments such as EQ-5D that are validated to be used in cost/QALY calculations, 
unlike disease specific instruments. cOnclusiOns: Contrary to the increasing aca-
demic interest in QoL and PRO endpoints, these have not yet translated into playing 
a significant role in payer decision making for new oncology products. Currently, 
QoL instruments are used in oncology clinical trials as standard protocol. However, 
differentiating one drug over another through an improvement demonstrated using 
QoL instruments does not yet directly translate to an advantage from a market 
access point of view for that drug.
site and access to patients who are home bound or located in remote geographic 
locations. This novel approach did not seem to alter the participant’s ability to 
participate in a qualitative study.
PCN148
ideNtifyiNg symPtoms aNd imPaCts exPeRieNCed by meN with NoN-
metastatiC CastRatioN ResistaNt PRostate CaNCeR
Moïse P.1, Tomaszewski E.L.2, Krupnick R.3, Baskin-Bey E.4, Meyer M.3, Holmstrom S.5
1Quintiles Consulting Europe, Levallois-Perret, France, 2Quintiles, Cambridge, MA, USA, 
3Quintiles Consulting, Cambridge, MA, USA, 4Astellas Pharma Global Development, Leiden, The 
Netherlands, 5Astellas Pharma Europe, Leiderdorp, The Netherlands
Objectives: We sought to identify the most relevant and important symptoms and 
impacts of non metastatic (M0) castration resistant prostate cancer (CRPC) from 
the patient’s perspective. MethOds: First, a literature review was performed that 
focused on symptoms related to living with M0 CRPC. Then, individual interviews 
with five clinicians experienced in treating PC were conducted to understand the 
clinical perspective of treating M0 CRPC. Finally, individual interviews with 17 M0 
CRPC patients were conducted following a semi-structured interview guide. Patients 
were asked about symptoms, impacts of living with M0 CRPC, and interference of 
symptoms with daily living and impacts on a scale of 0-10. Results: 35 unique 
symptoms were mentioned by patients: 15 patients mentioned erectile issues, 13 
loss of sexual desire, 11 urge to urinate, and 11 incontinence. No patient rated the 
interference of symptoms higher than a six on the impact scale. The most common 
impacts mentioned included: need to plan for urinary frequency (n= 9), interference 
with daily activities (n= 8), and anxiety (n= 7) or frustration (n= 7) over the diagnosis, 
symptoms, or treatment. Clinicians confirmed the symptoms expressed by patients 
and noted that many could be attributed to prior and/or current treatments for 
PC and not the PC itself, a finding observed consistently in the published litera-
ture. cOnclusiOns: The most relevant and important symptoms (erectile dys-
function, urinary symptoms, anxiety, and emotional impacts) expressed by patients 
aligned with those mentioned by clinicians and the literature. This data provides 
valuable insight into patients’ experience with M0 CRPC illustrating that the most 
relevant symptoms and impacts thereof expressed by patients may be attributed 
to PC therapy and not to the consequences of the M0 CRPC disease state itself.
PCN149
assessmeNt of ResPoNse shift aNd tRue ChaNge usiNg stRuCtuRal 
eQuatioN modeliNg foR health–Related Quality-of-life sCoRes iN 
PatieNts with bReast CaNCeR afteR suRgeRy
Nakamura K.1, Shimozuma K.1, Suzukamo Y.2, Taira N.3, Shiroiwa T.4, Shibahara H.1, Saito S.5
1Ritsumeikan University, Kusatsu, Japan, 2Tohoku Universitiy, Seidai, Japan, 3Okayama University 
Hospital, Okayama, Japan, 4National Institute of Public Health, Saitama, Japan, 5Okayama 
University, Okayama, Japan
Objectives: Response shift can be considered measurement bias in the assessment 
of HRQOL. The purpose of this study was to detect response shifts and true change 
in health-related quality-of-life (HRQOL) scores in patients with breast cancer after 
surgery using structural equation modeling (SEM) proposed by Oort F. J. MethOds: 
The HRQOL data set was derived from published in the ‘Breast Cancer Res Treat’ in 
2011 to reveal predictors of HRQOL scores 1 and 2 years after breast cancer surgery. 
HRQOL was assessed in patients with breast cancer (N= 196) using the Functional 
Assessment of Cancer Therapy – General (FACT-G) at baseline (1 month), 6, 12, and 
24 months after surgery. We developed models using ‘four domains’ (physical well-
being [PWB], social/family well-being [SWB], emotional well-being [EWB], and func-
tional well-being [FWB] subscales of the FACT-G) and ‘higher concept’ integrating 
four domains. Analyses were performed using Oort’s SEM (Software: IBM SPSS AMOS 
20.0) approach to detect response shifts and true change. Results: The following 
response shifts were detected: between baseline and 6 months, uniform recalibra-
tion and reprioritization in SWB and non-uniform recalibration in PWB; and between 
baseline and 12 months, uniform/non-uniform recalibration and reprioritization in 
SWB. True change was detected both between baseline and 6 months and between 
baseline and 12 months for overall QOL. cOnclusiOns: The analyses using the mod-
els developed in this study based on ‘four domains’ and ‘higher concept’ yielded more 
easily interpretable results compared to previously reported models based on ‘items’ 
and ‘domains’. The results of this study will help understand possible measurement 
bias due to response shift effects on the assessment of HRQOL in a longitudinal study.
PCN150
desigN aNd validatioN of a QuestioNNaiRe foR measuRiNg PeRCeived 
Risk of skiN CaNCeR
Morales-Sánchez MA1, Peralta-Pedrero ML2
1Centro Dermatológico “Dr. Ladislao de la Pascua”, Secretaría de Salud del D.F., Distrito Federal, 
Mexico, 2Centro Dermatológico “Dr. Ladislao de la Pascua”, Secretaría de Salud del D.F., Distrito 
Federal, Mexico
Objectives: The aim of this study was to design and validate a self-administered 
questionnaire for measuring the perceived risk of skin cancer. MethOds: A self-
administered questionnaire with a visual Likert-type scale was designed based on 
the results of the analysis of the content of a survey performed in 100 patients in the 
DrLadislao de la Pascua Skin Clinic, Distrito Federal México, Mexico. Subsequently, 
the questionnaire was administered to a sample of 359 adult patients who attended 
the clinic for the first time. As no gold standard exists for measuring the perceived 
risk of skin cancer, the construct was validated through factor analysis. Results: 
The final questionnaire had 18 items. The internal consistency measured with 
Cronbach alpha was 0.824 overall. In the factor analysis, 4 factors (denoted as affec-
tive, behavioral, severity, and susceptibility) and an indicator of risk accounted for 
65.133% of the variance. cOnclusiOns: The psychometric properties of the scale 
were appropriate for measuring the perception of risk in adult patients (aged 18 
years or more) who attended the dermatology clinic. This is the first questionnaire 
in spanish to measure perceived risk of skin cancer that serves to quantify the 
response to interventions for preventing this disease.
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not significantly different between the two treatment groups from baseline to end 
of treatment. However, there was a statistically significant improvement in Pain 
QLQ-C30 score from baseline to week 3 (OR= 3.14, p= 0.036) and week 6 (OR= 3.33, 
p= 0.034) in the metronomic arm compared with the cisplastin arm. cOnclusiOns: 
Understanding the impact of different treatment options on changes in QoL over 
time can not only aid physicians in communication with patients but also assist 
in the design of interventions that focus on rehabilitation of patients with head 
and neck cancer.
PCN158
health Related Quality of life amoNg PatieNts diagNosed with 
advaNCed NoN small Cell luNg CaNCeR iN iNdia
Prabhash K.1, Marfatia S.2, Patel M.2, Kamble S.2
1Tata Memorial Hospital, Mumbai, India, 2PharmEDGE, Mumbai, India
Objectives: To monitor changes in health related quality of life (HRQoL) among 
advanced stage non small cell lung cancer (NSCLC) patients receiving oral gefi-
tinib. MethOds: An observational study was conducted at the Tata Memorial 
Hospital, Mumbai, India, among stage-IV NSCLC patients who were > 18 years, had 
failed conventional chemotherapy, had EGFR mutation reports available, and were 
scheduled to receive oral gefitinib 250 mg OD treatment. Patients who met the 
inclusion criteria and agreed to participate in the study were recruited between 
January 1, 2010 and June 30, 2012. In addition to recording demographic and baseline 
clinical characteristics, patients were asked to rate their HRQoL using the European 
Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EORTC 
QLQ-LC13 questionnaires (Indian versions) at baseline and at every two months 
till the patient developed progressive disease or deteriorated in performance sta-
tus. Results: A total of 167 patients participated in the study. The mean age of 
study participants was 58.5 years (S.D.± 11.8). About 37.8% patients had a history 
of any kind of tobacco use. Significant improvements in overall quality of life were 
observed from baseline at week 16 (p= 0.001), week 24 (p= 0.02), and week 32 (p= 0.03). 
Furthermore, lung cancer symptom score (QLQ-LC-13) significantly decreased at 
week 8 (p= 0.019) and week 16 (p< < 0.01) as compared to baseline. Compared to 
baseline, pain in the arm and shoulder (QLQ-LC-13) decreased at week 8 (p= 0.008) 
and week 16 (p= 0.0025), as did pain in chest (QLQ-LC-13) at week 8 (p= 0.049) and 
week 16 (p= 0.003). cOnclusiOns: Gefitinib has not only shown a favorable toxicity 
profile but it has also demonstrated significant improvements over time in overall 
QoL, as well as, on domains such a symptom relief and pain. Therefore, Gefitinib 
could be considered as a viable treatment option in patients with advanced NSCLC.
PCN159
the assoCiatioN of ChemotheRaPy veRsus hoRmoNal theRaPy aNd 
health outComes amoNg PatieNts with hoRmoNe ReCePtoR-Positive, 
heR2-Negative metastatiC bReast CaNCeR: exPeRieNCe fRom the 
PatieNt PeRsPeCtive
Jerusalem G.1, Gupta S.2, Zhang J.3
1Centre Hospitalier Universitaire du Sart Tilman Liège, Liege, Belgium, 2Kantar Health, Princeton, 
NJ, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Objectives: Health-related quality of life (HRQoL) is essential in treatment deci-
sions for metastatic breast cancer (mBC), therefore, it’s important to understand 
the impact of treatment on patient-reported outcomes (PRO) in a real-world set-
ting. This study aims to characterize the impact of mBC and cancer treatments on 
HRQoL, treatment satisfaction and daily productivity from the patient perspec-
tive. MethOds: This is a cross-sectional survey of 360 patients with mBC (US, 
n= 200; EU, n= 160). Post-menopausal women aged ≥ 50 years, with hormone receptor 
positive (HR+), HER2-negative (HER2-) mBC, currently using hormonal therapy (HT) 
or using chemotherapy (CT) for ≤ 1 year were recruited. The Functional Assessment 
of Cancer Therapy–Breast (FACT-B), Work Productivity and Activity Impairment, 
Cancer Treatment Satisfaction Questionnaire (CTSQ), patient-centric questions 
related to mBC, demographics, and adverse events (AEs) were assessed across CT 
and HT users. Multivariate analyses compared CT vs. HT with adjustments for 
demographics, comorbidities, and disease/treatment related measures. Results: 
Among the 360 patients, 53% (n= 191) reported CT and 47% (n= 169) reported HT 
use. Patient characteristics were generally similar between treatment cohorts with 
an average age of 58.3 years (SD= 6.3). HT users reported higher FACT-B scores (78.0 
vs. 70.1, p< 0.001), higher scores on the FACT-B subscales (physical, emotional and 
functional well-being, and breast cancer, p< 0.05 for all), greater satisfaction with 
treatment (subscale of the CTSQ; 74.1 vs. 67.2, p< 0.001), and better feelings about 
side-effects (subscale of the CTSQ; 48.2 vs. 41.6, p< 0.001). HT users reported less 
bother with treatment AEs (0-5 scale, 1.0 vs. 1.3, p< 0.001) and less activity impair-
ment compared with CT (52.6% vs. 60.8%, p< 0.001). cOnclusiOns: Findings sug-
gest that HT is associated with better HRQoL, greater treatment satisfaction, less 
treatment related AEs, and less activity impairment compared with CT in 1st line 
mBC. These findings should be taken into consideration while making treatment 
decisions for HR+/HER2- mBC.
CaNCeR – health Care use & Policy studies
PCN160
Cost of disCoRdaNt diagNoses iN saRComa, gist, aNd desmoid tumoRs 
iN fRaNCe: Results fRom the RRePs (Reseau de RefeReNCe eN Pathologie 
des saRComes) NetwoRk
Perrier L.1, Rascle P.1, Ray-Coquard I.1, Bui Nguyen B.2, Morelle M.1, Ranchère Vince D.1, 
Terrier P.3, Neuville A.2, Decouvelaere A.V.1, Le Cesne A.3, Gomez F.1, de la Fouchardière C.1,  
Meeus P.1, Trédan O.1, Pérol M.1, Fayette J.1, Neidhardt E.M.1, Biron P.1, Boyle H.J.1,  
Marec-Bérard P.4, Farsi F.5, Ducimetière F.1, Blay J.Y.1, Coindre J.M.2
1Cancer Centre Léon Bérard, Lyon, France, 2Institut Bergonié, Bordeaux, France, 3Institut Gustave 
Roussy, Villejuif, France, 4IHOP, Lyon, France, 5Regional Oncology Network Réseau Espace Santé 
Cancer, Lyon, France
PCN155
imPRoved health-Related Quality of life iN PatieNts with 
ChRoNiC lymPhoCytiC leukemia tReated with ofatumumab Plus 
ChloRambuCil oR ChloRambuCil
Hillmen P.1, Haiderali A.2, Chang C.N.3
1St. James University Hospital, Leeds, UK, 2GlaxoSmithKline, Collegeville, PA, USA, 
3GlaxoSmithKline, Research Triangle Park, NC, USA
Objectives: The COMPLEMENT 1 trial demonstrated significantly better progres-
sion-free survival with ofatumumab combined with chlorambucil (O+CHL) [22.4 
months] versus chlorambucil alone (CHL) [13.1 months] in patients with chronic 
lymphocytic leukemia . The impact on health-related quality of life (HRQoL) was also 
assessed. MethOds: 447 previously untreated patients were randomized to receive 
3-12 cycles of O+CHL or CHL. The European Organization for Research and Treatment 
of Cancer (EORTC) QLQ-C30 and QLQ-CLL16 were administered at screening (base-
line), day 1 of cycles 4, 7, 10 and post-therapy. The pre-specified HRQoL outcomes 
were changes from baseline during and post therapy, and treatment differences in 
the two arms for Global Health Scale (GHS) of the QLQ-C30 and the Fatigue scale 
of the QLQ-CLL16. For treatment comparisons, mixed-model repeated measures 
(MMRM) analysis of covariance was used. Results: 428 patients completed at least 
one HRQoL assessment; with a median of 6 treatment cycles, cycle 10 had too few 
patients to analyze. For GHS, patients had improvements greater than the minimally 
important difference of 5 points for the CHL arm (Cycle 7) and for the O+CHL arm 
(Cycles 4 and 7). For the Fatigue scale, patients showed improvement from base-
line in both arms at Cycles 4 and 7. Most scales showed numerical improvements 
in both arms; exceptions were four scales in the CHL and two in the O+CHL arm. 
Post therapy, there were positive numerical changes from the last on-treatment 
visit in both arms for GHS and Fatigue scales. MMRM analysis showed no differ-
ences between treatment arms for GHS or Fatigue scales. cOnclusiOns: Patients 
receiving either O+CHL or CHL experienced improvements in HRQoL during therapy. 
Off treatment, patients continued to maintain or increase the improvements. The 
addition of ofatumumab to chlorambucil did not negatively impact HRQoL and may 
improve certain aspects of patients’ HRQoL during and after treatment.
PCN156
the assoCiatioN of ComoRbid aNxiety aNd mood disoRdeRs with 
health-Related Quality of life amoNg CaNCeR suRvivoRs
Park C., Kim G., Jiang S., Lawson K.A.
The University of Texas at Austin, Austin, TX, USA
Objectives: Cancer is related to lower health-related quality of life (HRQoL). 
However, little evidence exists regarding the marginal decrease in HRQoL by the 
presence of comorbid anxiety and mood disorders (bipolar and depressive disorders) 
among cancer survivors based on U.S population-based research. The objective of 
the study was to determine whether comorbid anxiety and mood disorders were 
associated decreased HRQoL among cancer survivors. MethOds: This cross-sec-
tional study used data from the 2011 Medical Expenditure Panel Surveys (MEPS). 
The independent variable was the presence of anxiety and/or mood disorders, and 
the dependent variable was HRQoL, which was measured using the SF-12 physical 
health composite scale (PCS) and mental health composite scale (MCS). Descriptive 
statistics, chi-square tests, and generalized linear models (GLM) were used for analy-
ses. Results: Among the estimated 17,987,639 cancer survivors, 9.4% had anxiety 
but not mood mood disorders, 11.4% had mood disorders but not anxiety, 3.8% 
had both anxiety and mood disorders, and 75.7% had neither anxiety nor mood 
disorders. The chi-square tests shows that the prevalence of anxiety and/or mood 
disorders was significantly different by age groups (p< 0.001), gender (p= 0.002), 
and perceived health status (p< 0.001), while it was not significantly different by 
race, insurance type, marital status, region, family income, and the presence of 
comorbidity. In the GLMs analyzing anxiety mood disorders separately, anxiety and 
mood disorders were both significantly associated with lower PCS scores (p= 0.002 
and p< 0.001) and MCS scores (both p< 0.001). After controlling for demographic 
and clinical factors, anxiety was not significantly associated with lower PCS scores 
(p= 0.235), but was associated with lower MCS scores (p= 0.005), and mood disorders 
were still significantly associated with both lower PCS (p= 0.006) and MCS (p< 0.001) 
scores. cOnclusiOns: Both anxiety and mood disorders were independently asso-
ciated with lower HRQoL among cancer survivors, but when controlling for other 
factors, mood disorders showed no association with the PCS.
PCN157
health Related Quality of life iN PatieNts with metastatiC, 
RelaPsed, oR iNoPeRable sQuamous Cell CaRCiNoma of the head aNd 
NeCk iN iNdia
Patil V.1, Prabhash K.1, Marfatia S.2, Patel M.2, Gupta K.2, Kamble S.2
1Tata Memorial Hospital, Mumbai, India, 2pharmEDGE, Mumbai, India
Objectives: Evaluate changes in health related quality of life (HRQoL) in patients 
with metastatic head and neck cancer randomized to receive either metronomic 
(methotrexate and celecoxib) or cisplatin chemotherapy. MethOds: Patients older 
than 18 years, Karnofsky performance score of > 70 and diagnosed with metastatic, 
locally advanced inoperable or recurrent head and neck cancer not amenable to 
surgery or radiation were randomized (1:1) to receive of metronomic or 6 cycles of 
cisplatin chemotherapy. All patients were recruited from the Tata Memorial Hospital 
(TMH), Mumbai, India. In addition to demographic and baseline clinical character-
istics, patients were asked to rate their HRQoL using the European Organization for 
Research and Treatment of Cancer (EORTC) QLQ-C30 and the EORTC QLQ-H&N35 
questionnaires (Indian versions) at baseline and at the end of each chemo-cycle 
(every three weeks) till the end of study (week 18) or early termination. Results: 
Of the 110 patients screened, 87 agreed to participate in the study. Mean age of the 
study population was 47.5 years (S.D.± 10.04) for the metronomic group and 47.2 
years (S.D.± 9.89) for the cisplatin group. Oral cavity was the primary site of cancer 
(metronomic arm: 77.8%; cisplatin arm: 71.4%). About 57.8% and 45.2% patients 
had a history of tobacco use in both treatment arms. Overall quality of life was 
